NCT03616431 (PanDA) is a clinical trial of Pancreo-KIT breath test in Pancreatic Neoplasm, sponsored by The Christie NHS Foundation Trust.

Who is sponsoring NCT03616431?

NCT03616431 is sponsored by The Christie NHS Foundation Trust.

What drugs are being tested in NCT03616431?

Interventions in NCT03616431: Pancreo-KIT breath test.

What condition does NCT03616431 study?

NCT03616431 studies Pancreatic Neoplasm, Pancreas Adenocarcinoma, Well-Differentiated Neuroendocrine Carcinoma, Malignant Neoplasm of Pancreas.

Is NCT03616431 still recruiting?

NCT03616431 is currently completed. Last updated 25 August 2023.

Last reviewed 2023-08-25 · How we verify

NCT03616431: PanDA

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Pancreatic Cancer Dietary Assessment Study

Completed Last updated 25 August 2023

What this trial tests

trial testing Pancreo-KIT breath test in Pancreatic Neoplasm in 112 participants. Completed in 31 May 2021.

Timeline

3 July 2018

Primary endpoint
30 October 2020

31 May 2021

Quick facts

Lead sponsor	The Christie NHS Foundation Trust
Status	Completed
Study type	OBSERVATIONAL
Enrollment	112
Start date	3 July 2018
Primary completion	30 October 2020
Estimated completion	31 May 2021
Sites	1 location across United Kingdom

Drugs / interventions tested

Pancreo-KIT breath test

Conditions studied

Pancreatic Neoplasm — all drugs for Pancreatic Neoplasm →
Pancreas Adenocarcinoma — all drugs for Pancreas Adenocarcinoma →
Well-Differentiated Neuroendocrine Carcinoma — all drugs for Well-Differentiated Neuroendocrine Carcinoma →
Malignant Neoplasm of Pancreas — all drugs for Malignant Neoplasm of Pancreas →

Sponsor

The Christie NHS Foundation Trust

Who can join

18 and older, any sex, with Pancreatic Neoplasm or Pancreas Adenocarcinoma. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This is a prospective observational study which aims to evaluate; The prevalence of pancreatic insufficiency in patients with pancreatic malignancies (adenocarcinoma and neuroendocrine tumours). The most appropriate diagnostic strategy. The impact that an adequate diagnosis and treatment may have on patients' outcome.

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

Evaluation and management of exocrine pancreatic insufficiency: pearls and pitfalls.
Ramsey ML, Hart PA, Forsmark CE. · · 2023 · cited 7× · PMID 37530731 · DOI 10.1097/mog.0000000000000951
Prospective Observational Study of Prevalence, Assessment and Treatment of Pancreatic Exocrine Insufficiency in Patients with Inoperable Pancreatic Malignancy (PANcreatic Cancer Dietary Assessment-PanDA).
Carnie LE, Shah D, Vaughan K, Kapacee ZA, et al · · 2023 · cited 4× · PMID 37190204 · DOI 10.3390/cancers15082277

Verify or expand the search:

Other recruiting trials for Pancreatic Neoplasm

Currently open trials in the same condition.

NCT06807437 — Lanreotide Versus Placebo Before Surgery to Prevent a Surgical Complication Called a Pancreatic Fistula · Phase 3 · recruiting
NCT05687123 — Testing the Addition of Sunitinib Malate to Lutetium Lu 177 Dotatate (Lutathera) in Pancreatic Neuroendocrine Tumors · Phase 1 · recruiting
NCT06122896 — Prospective Screening for Pancreatic Ductal Adenocarcinoma in High-Risk Individuals · EARLY_PHASE1 · recruiting
NCT06411795 — Rectus Sheath Block With Liposomal Bupivacaine Versus Thoracic Epidural Analgesia for Pain Control Following Pancreatodu · Phase 2 · recruiting
NCT05961982 — Evaluation of Endoscopic Ultrasound-Guided Radiofrequency Ablation for the Management of Pancreatic Tumors, ERASE Study · NA · recruiting

Other The Christie NHS Foundation Trust trials

Trials by the same sponsor.

NCT07183267 — Using Red Light Therapy to Ease Skin Side Effects and Mouth Side Effects, in Children and Young People Aged 0 to 16 Year · NA · not yet recruiting
NCT07268339 — A Phase III Randomised Control Clinical Trial of Radiotherapy With Radiosensitisation Versus Intravesical Bacillus Calme · Phase 3 · not yet recruiting
NCT06965101 — To Determine Whether it is Feasible to Treat Patients Requiring Urgent Radiotherapy Diagnosed With Metastatic Cord Compr · NA · recruiting
NCT05903430 — A Feasibility Study of MRI Guided Stereotactic Ablative Radiotherapy (MIDSECTION) · recruiting
NCT07202260 — Pragmatic Analysis of Complex Radiotherapy Cases In Cancer of the Lung · active not recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03616431 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by The Christie NHS Foundation Trust
Last refreshed: 25 August 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03616431.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing